753 related articles for article (PubMed ID: 22569112)
1. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
Iovieno N; Papakostas GI
J Clin Psychiatry; 2012 May; 73(5):676-83. PubMed ID: 22569112
[TBL] [Abstract][Full Text] [Related]
2. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis.
Iovieno N; Papakostas GI
J Clin Psychiatry; 2012 Oct; 73(10):1300-6. PubMed ID: 23140647
[TBL] [Abstract][Full Text] [Related]
3. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants.
Freeman MP; Mischoulon D; Tedeschini E; Goodness T; Cohen LS; Fava M; Papakostas GI
J Clin Psychiatry; 2010 Jun; 71(6):682-8. PubMed ID: 20573327
[TBL] [Abstract][Full Text] [Related]
4. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach.
Tedeschini E; Fava M; Papakostas GI
J Clin Psychiatry; 2011 Jan; 72(1):98-113. PubMed ID: 21208576
[TBL] [Abstract][Full Text] [Related]
5. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.
Papakostas GI; Fava M
Eur Neuropsychopharmacol; 2009 Jan; 19(1):34-40. PubMed ID: 18823760
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.
Tedeschini E; Levkovitz Y; Iovieno N; Ameral VE; Nelson JC; Papakostas GI
J Clin Psychiatry; 2011 Dec; 72(12):1660-8. PubMed ID: 22244025
[TBL] [Abstract][Full Text] [Related]
7. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.
Sinyor M; Levitt AJ; Cheung AH; Schaffer A; Kiss A; Dowlati Y; Lanctôt KL
J Clin Psychiatry; 2010 Mar; 71(3):270-9. PubMed ID: 20122371
[TBL] [Abstract][Full Text] [Related]
8. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials.
Iovieno N; Tedeschini E; Bentley KH; Evins AE; Papakostas GI
J Clin Psychiatry; 2011 Aug; 72(8):1144-51. PubMed ID: 21536001
[TBL] [Abstract][Full Text] [Related]
9. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
10. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
11. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
[TBL] [Abstract][Full Text] [Related]
12. Sponsorship, antidepressant dose, and outcome in major depressive disorder: meta-analysis of randomized controlled trials.
Sinyor M; Schaffer A; Smart KA; Levitt AJ; Lanctôt KL; Grysman NH
J Clin Psychiatry; 2012 Feb; 73(2):e277-87. PubMed ID: 22401489
[TBL] [Abstract][Full Text] [Related]
13. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
14. Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: a meta-analysis.
Tedeschini E; Fava M; Goodness TM; Papakostas GI
Eur Neuropsychopharmacol; 2010 Aug; 20(8):562-7. PubMed ID: 20219330
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy.
Nelson JC; Thase ME; Bellocchio EE; Rollin LM; Eudicone JM; McQuade RD; Marcus RN; Berman RM; Baker RA
Int Clin Psychopharmacol; 2012 May; 27(3):125-33. PubMed ID: 22466058
[TBL] [Abstract][Full Text] [Related]
16. Demographic variables, design characteristics, and effect sizes of randomized, placebo-controlled, monotherapy trials of major depressive disorder and bipolar depression.
Papakostas GI; Martinson MA; Fava M; Iovieno N
J Clin Psychiatry; 2016 May; 77(5):e619-24. PubMed ID: 27249092
[TBL] [Abstract][Full Text] [Related]
17. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.
Nelson JC; Papakostas GI
Am J Psychiatry; 2009 Sep; 166(9):980-91. PubMed ID: 19687129
[TBL] [Abstract][Full Text] [Related]
18. Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trials.
Iovieno N; Tedeschini E; Ameral VE; Rigatelli M; Papakostas GI
Int Clin Psychopharmacol; 2011 Mar; 26(2):69-74. PubMed ID: 20962663
[TBL] [Abstract][Full Text] [Related]
19. Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants.
Bauer M; Adli M; Bschor T; Pilhatsch M; Pfennig A; Sasse J; Schmid R; Lewitzka U
Neuropsychobiology; 2010; 62(1):36-42. PubMed ID: 20453533
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
